SciELO - Scientific Electronic Library Online

 
vol.23 número1Enfermedad de Parkinson en el estado de Michoacán, evolución y tratamientoRealidad virtual en rehabilitación de la marcha en niños con parálisis cerebral espástica índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay artículos similaresSimilares en SciELO

Compartir


Revista mexicana de neurociencia

versión On-line ISSN 2604-6180versión impresa ISSN 1665-5044

Rev. mex. neurocienc. vol.23 no.1 Ciudad de México ene./feb. 2022  Epub 28-Feb-2022

https://doi.org/10.24875/rmn.20000130 

Review articles

Repetitive transcranial magnetic stimulation for the treatment of anxiety disorders: A systematic review of the state-of-the-art

Estimulación magnética transcraneal repetitiva (EMTr) para el tratamiento de trastornos de ansiedad: una revisión sistemática del estado del arte

Luis F. Burguete-Castillejos1 

Flavio A. Domínguez-Pacheco1 

Claudia L. Martínez-González1  * 

1SEPI ESIME Zacatenco, Instituto Politécnico Nacional, Mexico City, Mexico


Abstract

Psychiatric disorders, particularly related to depression and anxiety, are emerging as the most disabling diseases of the new era. Finding different intervention methods to treat these conditions is a public health challenge. Thus, exploring the results obtained by transcranial magnetic stimulation (TMS) is critical since this neurostimulation technique could position itself as a blunt alternative to manage anxiety pathologies. In this review, a systematic search for TMS use in anxiety disorders was carried out based on the PRISMA criteria. It was found that the most effective protocol for TMS treatment for anxiety disorders is performed with low-frequency stimulation (1 Hz), with 110% of the motor threshold. Furthermore, repeated TMS has proven its effectiveness in different psychiatric disorders — not only as a therapeutic alternative but also in the search for neurological biomarkers—. TMS favors neuromodulation through the generation of action potentials, which facilitates the treatment of pathologies related to emotional components, such as anxiety. However, further research is needed to specify the neurobiological mechanisms present in the improvement of symptoms.

Keywords Anxiety disorders; Neurostimulation; Repeated transcranial magnetic stimulation

Resumen

Los trastornos psiquiátricos, particularmente los relacionados con depresión y ansiedad, se perfilan paulatinamente como las enfermedades más discapacitantes de la nueva era. Hallar diferentes métodos de intervención para tratar estas condiciones es un reto de salud pública. Por consecuencia, explorar los resultados obtenidos por la estimulación magnética transcraneal (EMTr) es crítico, ya que esta técnica de neuroestimulación puede posicionarse como una alternativa contundente para manejar las patologías de la ansiedad. En esta revisión se llevó a cabo una búsqueda sistemática del uso de la EMTr en trastornos de ansiedad con base en los criterios de PRISMA. Se encontró que el protocolo más efectivo de EMTr para trastornos de ansiedad se realiza a frecuencias bajas (1 Hz) y el área cortical estimulada es la prefrontal dorsolateral derecha. Además, la EMTr repetida ha probado su efectividad en diferentes trastornos psiquiátricos, no sólo como alternativa terapéutica, sino en la búsqueda de biomarcadores neurológicos. La EMTr favorece la neuromodulación a través de la generación de potenciales de acción, lo cual facilita el tratamiento de patologías relacionadas con componentes emocionales como la ansiedad. Sin embargo, aún se requiere mayor investigación para especificar los mecanismos neurobiológicos presentes en el mejoramiento de los síntomas.

Palabras clave Trastornos de ansiedad; Neuroestimulación; EMTr

Introduction

Anxiety and depression are the most widespread mental disorders, most prevalent in low- and middle-income countries — whose rate remains increasing in the world population due to social, economic, physical, and patient context factors1. This situation will generate more significant chain conflicts, and if the global burden of mental illness is considered, it will imply that contemporary society will eventually begin to need not only a higher amount of clinical alternatives to address these pathologies but more effective methods and techniques to treat them.

Then, clinical models for treating anxiety problems should consider this phenomenon from a transdisciplinary point of view, not to replace traditional intervention models, but to add the participation of neurosciences together with the use of technological tools2.

Transcranial magnetic stimulation (TMS) is an unorthodox and avant-garde treatment for clinical intervention3. Compared with traditional psychopharmacology, which aims to treat neurobiological mechanisms, TMS generates a stimulation directly in the functioning of any region of the cerebral cortex, both in inhibitory and excitatory neuronal circuits3. On the other hand, TMS affects neurophysiological processes and neurobiochemicals, without being invasive like some other procedures4, since it favors the depolarization of the membrane of neurons (Fig. 1) by generating a sufficient electromagnetic field to trigger action potentials5.

Figure 1 Depolarization is the process that allows the transmission of the nerve impulse when there is a change of charge between the outside of the membrane, from positive to negative, and the inside, from negative to positive. This process enables the transmission of the nerve impulse and, therefore, of the neuronal intercommunication. 

Compared to direct electrical stimulation, TMS allows stimulation to act more focally4. It has been considered that simple magnetic pulses or “trains” (pulse bursts) are capable of depolarizing the membrane of a group of neurons, either from some axon or some dendritic feet, initiating an exciting, or inhibiting chain reaction3.

The theoretical principles of magnetic induction proposed by Michael Faraday toward 1831 are the basis of the TMS. However, until 1984, Anthony Barker et al. managed, through extensive research, to develop a neurostimulator that could generate depolarization of cortical neurons, causing movements3. Eventually, the development of the stimulation technique gained its characteristics and stimulation parameters to turn it into what is currently known as the TMS.

TMS is a technique with a mechanism of action that consists in the application of a magnetic field (magnetic pulses) of defined intensity which is produced by a coil going through not only the skull but also the scalp of a person to reach the cerebral cortex, where it will affect, inhibiting or exciting, and neuronal function (Fig. 2)6.

Figure 2 Principles of transcranial magnetic stimulation. Sagittal brain section. 

Practically, for a magnetic neurostimulator to produce a magnetic field that is capable of stimulating cortical neurons, it must use an electric current intensity of 7-10 kA, which is produced by an energy capacitor, a charging circuit, and one of discharge, as well as with an electronic switch that flows through a coil up to 500 J in the form of a pulse of approximately 1-ms duration7.

This treatment has been well received by multiple international clinical institutions as a “non-experimental” medical treatment for psychiatric conditions, especially for the effective treatment for major depression and promising usefulness for social anxiety treatment8. Related to panic disorder, a study conducted by Dresler in 2009 reported a case in which TMS was able to modulate cortical functions during an emotional crisis, that is, a panic attack9.

The objectives of this review were to analyze how effective the TMS intervention has been found in anxiety disorders — according to the characteristics of the samples and the experimental designs — and to determine the implications for future interventions based on the PRISMA criteria10.

Anxiety disorders

Anxiety is an emotional state in which humans naturally express to certain environmental stimuli. Thus, anxiety, understood as a physiological chain reaction activated by the autonomic nervous system, alerts individuals to dangerous situations that arise in the surroundings manifesting itself as adaptive defensive behavior that allows human survival.

Methodology

A specific search was conducted in the scientific research repositories such as PUBMED, Neurology, Medline, Elsevier, and others that meet international criteria until 2020. The first search was performed using the following keywords:

Panic disorder AND Magnetic transcranial stimulation OR Repetitive magnetic transcranial stimulation OR TMS, Generalized Anxiety Disorder AND symptoms OR state, Social Anxiety Disorder OR specific phobia OR depression AND anxiety, depersonalization disorder OR Parkinson AND depression AND anxiety. These results were included by virtue that it could be analyzed how efficient repeated TMS (rTMS) was for anxiety symptoms.

Various studies were selected according to the following inclusion criteria presented in Table 1.

Table 1 Inclusion and exclusion criteria for literature search 

Inclusion criteria Exclusion criteria
Date of recent publication Date of non-recent publication
Date of publication not recent that provide information to contextualize the subject or lay historical foundations of the topics Date of non-recent publication and obsolete information
TMS is applied to some anxiety disorder TMS was not applied to any psychiatric disorder
Explains the TMS application protocol
Explains the consequences of the application of TMS

During the systematic review, research was found, beyond anxiety itself, highlighting emotional processing and, in some cases, using a technique with the same physical principle as TMS, called Intermittent Tetha Burst Stimulation (iTBS) or Intermittent Stimulation of Theta bursts. Unlike rTMS, which application varies from values below 1 Hz to 50 Hz, iTBS provides 10 bursts of three biphasic pulses of 100 ms at 50 Hz repeated at 200ms intervals, that is, 5Hz at theta frequency11.

Selected documents were classified according to the information and type of research. Thus, the literature search was performed as presented in Fig. 3. The information extracted from the articles was organized to recognize the characteristics of the sample, experimental design, inclusion and exclusion criteria, the method and instrument of intervention, adverse symptoms, and results. The articles were rated according to the guidelines of the PEDro Scale12.

Figure 3 Literature search process. 

Results

The papers selected for the critical analysis of this systematic review are presented in Table 1. It is worth noting that the intervention method and the results were highlighted since this allows determining whether rTMS is emerging as a useful technique for anxiety disorder treatment and other disorders that also present anxiety symptoms.

Discussion

It was found that TMS, applied as a non-invasive intervention technique, is effective for different psychiatric disorders. Although the results of rTMS have been mostly studied in depression, it has been found that enough research has also been done in other pathologies such as those of anxiety.

The results have been organized and classified according to the effectiveness of treatment through rTMS, according to data within table 2.

Table 2 Organization of investigations according to effectiveness results 

Disorder/mental process Effective treatment Non-effective treatment
Disorder of panic/anguish García-Toro et al.14; Deppermann et al.43;
Machado et al.42; Zwanzger et al.41
Mantovani et al.39
Disorder of general anxiety Diefenbach et al.13
Anxiety/symptoms/state of anxiety/fear and anxiety Balconi and Ferrari19,20,26 Baeken et al.24;
Machado et al.15; Vanderhasselt et al.25
Vanderhasselt et al.23;
Zwanzger et al.28
Anxiety/social phobia Pallanti et al.36;
Balderson et al.45
Specific phobia Deppermann et al.29; Deppermann et al.33;
Herrmann30 Notzon et al.34
Anxious depression/depression and anxiety Diefenbach et al.18;
LaSalle-Ricci et al.21
Depression Deppermann et al.29;
Fitzgerald et al.27
Depersonalization Jay et al.16
Parkinson, anxiety and depression Kormos22
Automatic emotional reactions/emotional processing Berger et al.31; Vennewald et al.32
De Raedt et al.38

Studied disorders

According to the 34 studies collected (33 = 100%, considering the references Machado et al.15 and Paes et al.17 report two investigations), 66.66% were carried out with some specific disorder or symptoms of anxiety (23 = 100%). Therefore, 35.29% were performed with panic disorder, 17.64% were performed with phobic disorders, and 47.05% were performed with anxiety symptoms or some unspecified disorder of anxiety.

Sample description

Regarding the sample size, 36.36% of the studies were conducted with 30 or more participants. Samples of 67 and 40 patients were used for the disorder of panic, other samples of 25 and 30 patients were used for anxiety symptoms or some disorder of anxiety not specified and, in the case of phobias, all the samples were between 41 and 30 patients.

In general, these studies were carried out in hospitals. On the other hand, 64.70% were performed with very variable samples from < 30 patients. For example, in generalized anxiety, it was found that an investigation used a sample of 25 patients and other 10. There was more variability for the panic disorder since small samples were found between three and 15 volunteers; the same happened for symptoms or some unspecified disorder of anxiety, where samples were presented in the range of 10 to 28 participants.

Table 3 describes some other attributes of samples specified in the papers found during the systematic search.

Table 3 Other sample characteristics 

Sample characteristic Percentage of papers indicating attributes
Both genres 14.70%
Female gender 14.70%
Age range 8.82%
Over 18 years 2.94%
Over 40 years 2.94%
Right-handed manual preference 20.58%
Visual acuity 5.88%

Criteria for inclusion and exclusion of studies

Due to the inclusion and exclusion criteria, roughly, subjects had to be diagnosed according to specific scales with the study pathology, and in counterpart, not suffering any other disease of the central nervous system, psychiatric or neurological, or cardiovascular; only the concomitance of some other disease was allowed in Mantovani et al.39 and Mantovani et al.40 In none of the cases, the selection of volunteers was made according to gender.

Intervention protocol and treatment efficiency

Intervention protocol for anxiety disorders prevailing was 1 Hz with an intensity between 90 and 110% of the motor threshold, and it is essential to note that there is a correlation between stimulation characteristics and its results. Notably, in Zwanzger et al.41, treatment was carried out at a low frequency, but it was not performed repeatedly, and the results were not as expected. Regarding the results of Deppermann et al.43, no strong results were found since the registered psychophysiological arousal may be due to the tasks performed by those evaluated and not properly to the effects of stimulation; the results of Vanderhasselt et al.23 and Baeken et al.24 had no favorable effects because the stimulation was performed with high frequencies (10 Hz) as the frequency approved for depression.

Results presented in Deppermann et al.33 are inconclusive by virtue that it cannot be specified how stimulation modulates neuronal activation. On the other hand, Notzon34 stated that a single stimulation session is not enough to generate effects on phobic symptoms, and mainly the frequency of the protocol was not presented. The results presented in Balconi19,20 were favorable, although protocols with an intermediate intensity (5 Hz) were applied. In other words, 72.72% of the sources consulted showed favorable results after using the rTMS, while 27.27% indicated non-favorable or conclusive results, although it should be noted that the protocol is not the same in all cases. In this context, 68.18% stimulated the right dorsolateral prefrontal cortex, demonstrating that the efficacy of rTMS treatment for these types of disorders is achieved when this neuroanatomic region is stimulated, because it reduces hypermetabolism and neuronal hyperexcitability.

Neurostimulation equipment used for rTMS

The most used neurostimulator, as reported in the documents was Magstim18,19,22,23,25,42, followed by Dantec MagPRo14,28-30, and only one report13 used Neuronetics XPLOR, and other one MagVenture MagPro 10045.

Adverse reactions reported

In the present review, Baeken et al.24 reported a secondary dermatological reaction; García-Toro et al.14, a patient who reported mild and transient headache, and Diefenbach et al.13 reported that one patient suffered pain at the stimulation site. Although the administration of this neurostimulation technique is endorsed by the Food and Drug Administration (FDA), results indicate that it is favorable, it has been indicated that research on the effects should continue. It is important to mention that research using functional neuronal evaluation tools in which clinical factors can be ruled out to demonstrate the effects of magnetic stimulation is needed.

In two studies, there was a control group analysis with a placebo effect13,43, and it was possible to show that magnetic stimulation was effective in Diefenbach et al.13, which is not in Deppermann’s43.

Limitations of this review

Although conventional intervention methods, which include psychotherapy and pharmacology, have proven to be effective because both have been studied for a long time, protocols need to conclude whether magnetic stimulation effects are effective or not. About the above, it should be considered that subjective variables, that is, the references of the patients about their perception of improvement, do not allow a more objective analysis, and it is necessary to carry out the evaluation of the effect with functional and structural evaluation tools of the stimulated cortical areas.

On the other hand, it is worth noting that no studies were found in which rTMS has been used during a panic attack so that its effect on physiological or other variables could be understood in greater depth. In the same way, this systematic review of literature aimed to determine how effective rTMS is in anxiety disorders, highlighting the importance of continuing the research on the topic.

Regarding to the PEDro scale, one article fulfilled 100% of the criteria, six with 90.90%, three with 27.27%, one with 72.72%, one with 63.63%, and four with 54.54%, while the rest of the works were found below this last percentage, so it could be said that half of the papers reported met at least more than half of the criteria established in the scale PEDro. In this regard, it is necessary for scientific research to demonstrate the usefulness of any clinical intervention, in this case the rTMS in anxiety disorders, and expose the risks of bias, either due to the characteristics of the samples or the non-contemplation of certain variables, as well as to break down their design, their procedures and results explicitly so that other researchers clearly know the benefits.

Conclusions

rTMS favors neuromodulation through the generation of action potentials6, which facilitates the treatment of pathologies related to emotional components, such as anxiety.

The most effective protocol to treat anxiety disorders with the reported rTMS uses low-frequency stimulation (1 Hz), with 110% of the motor threshold, applied on the right dorsolateral prefrontal cortex with a 30-min train 5 times a week, for a month.

Finally, the use of rTMS could favor efficacy of psychotherapeutic procedures since these are understood as methods favoring learning, and neurostimulation promotes neuroplasticity.

SUPPLEMENTARY DATA

Supplementary data are available at DOI: 10.24875/RMN.20000130. These data are provided by the corresponding author and published online for the benefit of the reader. The contents of supplementary data are the sole responsibility of the authors.

References

1. Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, et al. PRISMA harms checklist:improving harms reporting in systematic reviews. BMJ. 2016;352:i157. [ Links ]

2. Koutsimani P, Montgomery A, Georganta K. The relationship between burnout, depression, and anxiety:a systematic review and meta-analysis. Front Psychol. 2019;10:284. [ Links ]

3. Alonzo A, Aaronson S, Bikson M, Husain M, Lisanby S, Martin D, et al. Study design and methodology for a multicentre, randomised controlled trial of transcranial direct current stimulation as a treatment for unipolar and bipolar depression. Contemp Clin Trials. 2016;51:65-71. [ Links ]

4. Pascual-Leone A, Tormos-Muñoz JM. Estimulación Magnética Transcraneal:fundamentos y Potencial de la Modulación de Redes Neurales Específicas;2008. Available from:http://www.cecm.usp.br/~eris/pub/artigos/cognicao/pascual-leone_EMT.pdf. [Last accessed on 2018 Aug 28]. [ Links ]

5. Jiménez-Genchi A, González-Olvera J, Guerrero AG. Las aplicaciones de la estimulación magnética transcraneal en psiquiatría. Salud Ment. 2002;25:033040. [ Links ]

6. Brunoni AR, Teng CT, Correa C, Imamura M, Brasil-Neto JP, Boechat R, et al. Neuromodulation approaches for the treatment of major depression:challenges and recommendations from a working group meeting. Arq Neuropsiquiatr. 2010;68:433-51. [ Links ]

7. León M, Rodríguez ML, Sanjuán L, Benito-León J, García-Albea Ristol E, et al. Current evidence on transcranial magnetic stimulation and its potential usefulness in post-stroke neurorehabilitation:opening new doors to the treatment of cerebrovascular disease. Neurologia. 2018;33:459-72. [ Links ]

8. Pascual-Leone A. Handbook of transcranial magnetic stimulation. J Psychiatry Neurosci. 2003;28:373-5. [ Links ]

9. Pallanti S, Bernardi S. Neurobiology of repeated transcranial magnetic stimulation in the treatment of anxiety:a critical review. Int Clin Psychopharmacol. 2009;24:163-73. [ Links ]

10. Dresler T, Ehlis AC, Plichta MM, Richter MM, Jabs B, Lesch KP, et al. Panic disorder and a possible treatment approach by means of high-frequency rTMS:a case report. World J Biol Psychiatry. 2009;10:991-7. [ Links ]

11. Dieguez-Varela C, Lion-Vazquez S, Fraga-Bau A, Rodriguez-Acevedo B, Rodriguez-Sanchez L, Collazo-Dieguez M, et al. Intermittent theta-burst transcranial magnetic stimulation for the treatment of spasticity in patients with recurring multiple sclerosis:the results of a double-blind randomised clinical trial. Rev Neurol. 2019;69:45-52. [ Links ]

12. Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M. Reliability of the PEDro scale for rating quality of randomized controlled trials. Phys Ther. 2003;83:713-21. [ Links ]

13. Diefenbach GJ, Bragdon L, Zertuche L, Hyatt CJ, Hallion LS, Tolin DF, et al. Repetitive transcranial magnetic stimulation for generalised anxiety disorder:a pilot randomised, double-blind, sham-controlled trial. Br J Psychiatry. 2016;209:222-8. [ Links ]

14. García-Toro M, Salva Coll J, CrespíFont M, Andrés Tauler J, Aguirre Orue I, Bosch Calero C. Trastorno de angustia y estimulación magnética transcraneal. Actas Esp Psiquiatr. 2002;30:221-4. [ Links ]

15. Machado S, Paes F, Velasques B, Teixeira S, Piedade R, Ribeiro P, et al. Is rTMS an effective therapeutic strategy that can be used to treat anxiety disorders?Neuropharmacology. 2012;62:125-34. [ Links ]

16. Jay EL, Nestler S, Sierra M, McClelland J, Kekic M, David AS. Ventrolateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of depersonalization disorder:a consecutive case series. Psychiatry Res. 2016;240:118-22. [ Links ]

17. Paes F, Baczynski T, Novaes F, Marinho T, Arias-Carrión O, Budde H, et al. Repetitive transcranial magnetic stimulation (rTMS) to treat social anxiety disorder:case reports and a review of the literature. Clin Pract Epidemiol Ment Health. 2013;9:180-8. [ Links ]

18. Diefenbach GJ, Bragdon L, Goethe JW. Treating anxious depression using repetitive transcranial magnetic stimulation. J Affect Disord. 2013;151:365-8. [ Links ]

19. Balconi M, Ferrari C. Left DLPFC rTMS stimulation reduced the anxiety bias effect or how to restore the positive memory processing in high-anxiety subjects. Psychiatry Res. 2013;209:554-9. [ Links ]

20. Balconi M, Ferrari C. Repeated transcranial magnetic stimulation on dorsolateral prefrontal cortex improves performance in emotional memory retrieval as a function of level of anxiety and stimulus valence. Psychiatry Clin Neurosci. 2013;67:210-8. [ Links ]

21. LaSalle-Ricci VH, Sisko E, DeBlasio K, Tendler S, Allsup H, DeLuca L, et al. Early improvement of depression and anxiety symptoms with repetitive transcranial magnetic stimulation (rTMS) augmentation of medication:case series. Brain Stimul. 2014;7:e20-1. [ Links ]

22. Kormos TC. Efficacy of rTMS in the treatment of co-morbid anxiety in depressed patients with Parkinson's disease. Mov Disord. 2007;22:1836-6. [ Links ]

23. Vanderhasselt MA, Baeken C, Hendricks M, De Raedt R. The effects of high frequency rTMS on negative attentional bias are influenced by baseline state anxiety. Neuropsychologia. 2011;49:1824-30. [ Links ]

24. Baeken C, Vanderhasselt MA, De Raedt R. Baseline state anxiety influences HPA-axis sensitivity to one sham-controlled HF-rTMS session applied to the right dorsolateral prefrontal cortex. Psychoneuroendocrinology. 2011;36:60-7. [ Links ]

25. Vanderhasselt MA, Baeken C, De Raedt R. S17.3 Baseline state anxiety influences the effects of high frequency rTMS to the right prefrontal cortex on attentional processes for emotional material. Clin Neurophysiol. 2011;122:S40-1. [ Links ]

26. Balconi M, Ferrari C. RTMS stimulation on left dlpfc affects emotional cue retrieval as a function of anxiety level and gender. Depress Anxiety. 2012;29:976-82. [ Links ]

27. Fitzgerald PB, Hoy KE, Anderson RJ, Daskalakis ZJ. A study of the pattern of response to rTMS tratment in depression. Depress Anxiety. 2016;33:746-53. [ Links ]

28. Zwanzger P, Steinberg C, Rehbein MA, Bröckelmann AK, Dobel C, Zavorotnyy M, et al. Inhibitory repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex modulates early affective processing. Neuroimage. 2014;101:193-203. [ Links ]

29. Deppermann S, Notzon S, Kroczek A, Rosenbaum D, Haeussinger FB, Diemer J, et al. Functional co-activation within the prefrontal cortex supports the maintenance of behavioural performance in fear-relevant situations before an iTBS modulated virtual reality challenge in participants with spider phobia. Behav Brain Res. 2016;307:208-17. [ Links ]

30. Herrmann MJ, Katzorke A, Busch Y, Gromer D, Polak T, Pauli P, et al. Medial prefrontal cortex stimulation accelerates therapy response of exposure therapy in acrophobia. Brain Stimul. 2017;10:291-7. [ Links ]

31. Berger C, Domes G, Balschat J, Thome J, Höppner J. Effects of prefrontal rTMS on autonomic reactions to affective pictures. J Neural Transm. 2017;124:139-52. [ Links ]

32. Vennewald N, Winter B, Limburg K, Diemer J, Notzon S, Fohrbeck I, et al. Emotional processing and rTMS:does inhibitory theta burst stimulation affect the human startle reflex?J Neural Transm. 2016;123:1121-31. [ Links ]

33. Deppermann S, Notzon S, Britz R, Wirsing D, Kroczek A, Haeussinger FB, et al. P73. Can iTBS modulate subjective and objective parameters of emotional processing in fear-relevant situations?A pilot study with spider phobics. Clin Neurophysiol. 2015;126:e130-1. [ Links ]

34. Notzon S, Deppermann S, Fallgatter A, Diemer J, Kroczek A, Domschke K, et al. Psychophysiological effects of an iTBS modulated virtual reality challenge including participants with spider phobia. Biol Psychol. 2015;112:66-76. [ Links ]

35. Downar J, Blumberger DM, Daskalakis ZJ. The neural crossroads of psychiatric illness:an emerging target for brain stimulation. Trends Cogn Sci. 2016;20:107-20. [ Links ]

36. Pallanti S, Borgheresi A, Pampaloni I, Giovannelli F, Bernardi S, Cantisani A, et al. Motor cortex excitability correlates with novelty seeking in social anxiety:a transcranial magnetic stimulation investigation. J Neurol. 2010;257:1362-8. [ Links ]

37. Baeken C, De Raedt R, Van Schuerbeek P, Vanderhasselt MA, De Mey J, Bossuyt A, et al. Right prefrontal HF-rTMS attenuates right amygdala processing of negatively valenced emotional stimuli in healthy females. Behav Brain Res. 2010;214:450-5. [ Links ]

38. De Raedt R, Leyman L, Baeken C, Van Schuerbeek P, Luypaert R, Vanderhasselt MA, et al. Neurocognitive effects of HF-rTMS over the dorsolateral prefrontal cortex on the attentional processing of emotional information in healthy women:an event-related fMRI study. Biol Psychol. 2010;85:487-95. [ Links ]

39. Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S. Repetitive transcranial magnetic stimulation (rTMS) in the treatment of panic disorder (PD) with comorbid major depression. J Affect Disord. 2007;102:277-80. [ Links ]

40. Mantovani A, Aly M, Dagan Y, Allart A, Lisanby SH. Randomized sham controlled trial of repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex for the treatment of panic disorder with comorbid major depression. J Affect Disord. 2013;144:153-9. [ Links ]

41. Zwanzger P, Eser D, Völkel N, Baghai TC, Möller HJ, Rupprecht R, et al. Effects of repetitive transcranial magnetic stimulation (rTMS) on panic attacks induced by cholecystokinin-tetrapeptide (CCK-4). Int J Neuropsychopharmacol. 2007;10:285-9. [ Links ]

42. Machado S, Santos V, Paes F, Arias-Carrión O, Carta MG, Silva AC, et al. Repetitive transcranial magnetic stimulation (rTMS) to treat refractory panic disorder patient:a case report. CNS Neurol Disord Drug Targets. 2014;13:1075-8. [ Links ]

43. Deppermann S, Vennewald N, Diemer J, Sickinger S, Haeussinger FB, Notzon S, et al. Does rTMS alter neurocognitive functioning in patients with panic disorder/agoraphobia?An fNIRS-based investigation of prefrontal activation during a cognitive task and its modulation via sham-controlled rTMS. Biomed Res Int. 2014;2014:542526. [ Links ]

44. Li H, Wang J, Li C, Xiao Z. Repetitive transcranial magnetic stimulation (rTMS) for panic disorder in adults. Cochrane Database Syst Rev. 2014;2014:CD009083. [ Links ]

45. Balderston NL, Beydler EM, Goodwin M, De Deng Z, Radman T, Luber B, et al. Low-frequency parietal repetitive transcranial magnetic stimulation reduces fear and anxiety. Transl Psychyatry. 2020;10. https://doi.org/10.1038/s41398-020-0751-8. [ Links ]

Supplementary Table 1 Repeated transcranial magnetic stimulation in psychiatric disorders of anxiety, depression, and others 

Ref./year/disorder/PEDro score Sample/design Inclusion criteria Exclusion criteria Method Stimulation and measurement instruments Adverse symptoms Results
Diefenbach et al., 201613
Generalized anxiety
PEDro Score: 8
13 patients with rTMS treatment and 12 patients with simulated treatment
Age ≤ 18
Randomized double-blind, sham-controlled trial design.
Age ≥ 18 years.
Diagnosis of generalized anxiety disorder.
Stabilization of drug treatment.
Traumatic brain injury and neurological diseases; epilepsy.
Heart or thyroid disease.
Disorder of stress
Substance use and abuse in the past.
Bipolar, psychotic, developmental, obsessive compulsive or other acute psychiatric disorders.
Psychotherapy.
1 Hz for 15 min. (900 pulses per session).
90% intensity of the engine at rest.
30 sessions (5 days/week for 6 weeks).
27,000 total pulses.
Right dorsolateral prefrontal cortex.
Neuronetics XPLOR coil Pain at the stimulation site.
Facial nerve contraction
Headache.
Dental pain.
Chest pain not related to intervention.
Clear evidence of the efficacy, anxiolytic effects, activation of the right dorsolateral prefrontal cortex
García-Toro et al., 200214
Anguish
PEDro Score: 2
3 patients, 1 female and 2 males.
Age 25, 30, and 57.
Case study.
1 Hz with a 20-30 s interval between trains. 30 trains at 110% of motor threshold.
60 s long
1 800 pulses, 10 sessions.
Right dorsolateral prefrontal cortex.
DANTEC, model MagPro. Mild and transient headache Very low and partial symptomatic improvement, not seem clinically significant.
Machado et al., 201215
Panic
PEDro Score: 0
15 patients.
No age references.
Sham-controlled trial design.
Drug-resistant. 10 sessions, 5 days a week, for 2 months.
1 Hz at 110% of motor threshold.
Right dorsolateral prefrontal cortex.
Significant reduction in anxiety symptoms, no marked differences between each group
Jay et al., 201616
Depersonalization
PEDro Score: 5
Seven patients, two females, and five males.
No age references.
Case-series design.
Depersonalization disorder diagnosis.
Informed consent.
Migraine and severe headaches.
Neurological disorders.
Any medical illness.
Family history with seizure disorders.
Without psychotherapeutic treatment.
Right ventrolateral prefrontal cortex. Depersonalization symptom scores reduced by 44% (Cambridge Depersonalization Scale)
Paes et al., 201317
General anxiety
PEDro Score: 0
10 patients.
Age range 18-56.
Open label design.
1 Hz, with 90% motor threshold.
6 sessions (2 days a week for 3 weeks).
Right dorsolateral prefrontal cortex.
Significant narrowing of anxiety symptoms (Hamilton Anxiety Scale scores).
Diefenbach et al., 201318
Anxious depression
PEDro Score: 4
32 patients.
Mean age = 55.9
Randomized controlled trials design.
Anxious depression diagnosis Motor threshold at 80-130%.
10 pulses per s and a 4 s stimulus train and 20-26 off.
31 sessions of 37.5 min for a total of 3000 and 5000 pulses.
Left dorsolateral prefrontal cortex.
Neuronetics
Neurostar TMS Therapy System
Significantly lower scores on the anxiety scale.
Balcony and Ferrari, 201319
Anxiety
PEDro Score: 4
28 patients, 17 females and 11 males.
Age range 21-39.
Two groups trials design.
Middle education level.
Right-handed subjects.
Normal visual acuity
Neurological or psychiatric pathologies. 5 Hz at 100% of motor threshold, 90 trains.
Left dorsolateral prefrontal cortex.
Magstim Super Rapid 2 with an eight-shaped coil. Improvement of anxiety (State-trait Anxiety Inventory).
Balcony and Ferrari, 201320
Anxiety
PEDro Score: 4
27 patients, 15 females and 12 males.
Age range 21-36.
Two groups trials design.
Age range between 21 and 36 years.
Right-handed
Normal visual acuity
History of psychopathology in the subjects or in the immediate family line. 5 Hz with train interval of 5 s at 100% of the motor threshold.
Left dorsolateral prefrontal cortex.
Magstim Super Rapid 2 with an eight-shaped coil. Recovery of positive emotional memory.
State-trait Anxiety Inventory, decreased the old negative stimuli (memories) related to anxiety.
LaSalle-Ricci et al., 201421
Depression and anxiety
PEDro Score: 4
33 patients.
No age references.
No design data.
2,000 pulses at 1 Hz with 80% motor threshold.
Right dorsolateral prefrontal cortex.
Neurostar Significant reduction in anxiety and depression. Through the Beck II Depression Inventory.
Kormos, 200722
Parkinson's, anxiety and depression treatment
PEDro Score: 5
Seven patients, two females, and five males.
Age range 62-79.
Case-series design.
Women or men 40 years and older.
Diagnosis of idiopathic Parkinson's disease.
Diagnosis of major depression or bipolar I disorder.
2000 pulses in 10 treatments in 2 weeks.
20 Hz with 80% motor threshold.
On for 2 s and off for 28 s, for 25 min.
Left dorsolateral prefrontal cortex.
Neopulse TMS Favorable efficacy to treat anxiety concomitant with Parkinson's disease (decrease of symptoms determined through Hamilton Depression Scale).
Vanderhasselt et al., 200723
Anxiety
PEDro Score: 9
28 females.
Age range 18-29.
Sham controlled double blind crossover design.
Only women 10 Hz, with 1560 pulses per 20 min session.
110% motor threshold.
40 trains, 3.9 s with 26.1 s of separation.
Right dorsolateral prefrontal cortex.
Magstim Corpumed Sheffield No effect on self-reported emotions.
No significative (State-trait Anxiety Inventory).
Baeken et al., 201124
Anxiety symptoms
PEDro Score: 10
24 patients.
Mean age 22.29.
Sham controlled, single blind crossover design.
Right-handed No use of medication or drugs.
Presence of some psychiatric disorder.
10 Hz at a stimulation intensity of 110% motor threshold.
40 trains, 3.9 s, with 26.1 s of separation, 1560 pulses per session.
Right dorsolateral prefrontal cortex.
Magstim Company Limited. Secondary dermatological reaction Global endocrinological production is not immediately affected by rTMS. POMS-Depression Scale and salivary cortisol, showed significant
Vanderhasselt et al., 201125
State of anxiety
PEDro Score: 1
28 females.
Sham controlled, randomized design.
Sham controlled session.
Right dorsolateral prefrontal cortex. One session had no effect on the mood. State Anxiety Inventory suggest that the increase in anxiety is due to the deficit of attention control.
Balconi and Ferrari, 201226
Anxiety symptoms
PEDro Score: 6
30 patients, 17 females and 13 males.
Age range 21-33.
Two groups trials design.
Right-handed.
Normal visual acuity.
History of depression in patient history or background in the immediate family. 5Hz at 100% motor threshold.
90 trains lasting 1 s with intervals of 5 .
Left dorsolateral prefrontal cortex.
Magstim Super Rapid.
Beck Depression Inventory.
State-Trait-Anxiety Inventory (STAI).
Favorable behavior in the recovery of emotional memories.
Fitzgerald et al., 201627
Depression
PEDro Score: 6
1 132 reviewed cases, 711 females and 419 males.
Age range 18-89.
11 clinical trials analysis.
10 Hz in the left dorsolateral prefrontal cortex, 1 Hz in the left and bilateral. Hamilton Depression Rating Scale (HAMD).
Montgomery Asberg rating scale (MADRS).
57% of the subjects experienced a substantial improvement of symptoms of depression Greater efficacy on left dorsolateral.
Zwanzger et al., 201428
Anxiety
PEDro Score: 9
40 patients, 23 females and 17 males.
Age range 19-38.
Control group with sham stimulation design.
Right-handed. Normal visual acuity. Neurological or psychiatric disorder. 1 Hz for 30 min at 120% motor threshold.
Right dorsolateral prefrontal cortex.
MagVenture MagPro x 100 (Magventure, Farum, Denmark).
Magnetoencephalography.
A global increase in neuronal activity, favorable emotional responses.
Deppermann et al., 201629
Specific phobia (arachnophobia)
PEDro Score: 7
41 patients with spider phobia and 42 controlls.
Age range 18-65.
Single-blind randomized sham-controlled group design.
Specific phobia (arachnophobia).
18-65 years-old
Other psychiatric disorders.
Another specific phobia.
Organic mental disorder.
Somatic diseases
Hypertension.
Pregnancy or breastfeeding
80% motor threshold.
Left dorsolateral prefrontal cortex.
MagOption MagPro x100.
Functional near-infrared spectroscopy
Tetha wave stimulation has a direct effect with emotional regulation.
Herrmann et al., 201730
Specific phobia (acrophobia)
PEDro Score: 10
39 patients.
Mean age 44.9
Two groups active versus sham design.
Specific phobia (acrophobia). Previous treatment for phobia.
Have metal pieces on the head.
Medical implants
High intracranial pressure
Pregnancy.
Active psychopharmacological or psychotherapeutic treatment.
Neurological or vascular pathologies.
10 Hz, with 100% motor threshold.
40 trains of 4 s, separated by 26 s.
1560 pulses in total.
Left dorsolateral prefrontal cortex.
MedTronic MagPro x100.
Acrophobia Questionnaire (AQ).
Behavioral Avoidance Test (BAT).
Subjective Units of Discomfort (SUD).
Attitude Towards Heights Questionnaire (ATHQ).
State-Trait Anxiety Inventory (STAI).
Anxiety Sensitivity Index-3 (ASI3).
General Positive and Negative Affective State (PANAS).
Depressive symptoms (ADS; Allgemeine Depressions Skala).
rTMS could work as a therapeutic complement for exposure therapies related to phobias.
Berger et al., 201731
Automatic emotional reactions
PEDro Score: 10
40 females.
Mean age 24
Single blind, placebo controlled, cross over design.
Right-handed. Psychiatric or somatic disorders.
Use of any medication or abuse of toxic substances.
10 Hz with 110% motor threshold. 18 trains with a total of 900 pulses for 5 s, with intervals of 10 s, total 4.5 min.
1 Hz for 15 continuous min total 900 pulses.
Right dorsolateral prefrontal cortex.
MCF-B65, Magpro 30, MagVenture GmbH, Huckelhoven, Germany.
General Positive and Negative Affective State (PANAS).
Empathizing, Systemizing and Autism-Spectrum Quotient.
Beck Depression Inventory (BDI).
NEO-Five Factor Inventory (NEOFFI).
State-Trait Anxiety Inventory (STAI).
International Affective Picture System (IAPS).
Electrocardiogram. Phasic cardiac responses (PCR).
Skin conductance reactions (SCR).
Influenced the heart rate response and on cortical arousal, no effect on emotional (subjective) processing.
Vennewald et al., 201632
Emotional processing
PEDro Score: 5
102 patients, 54 females and 48 males.
Mean age 24.95
Sham controlled, randomized design.
Current or previous diagnosis of DSM-IV axis-I. Neurological or other somatic disorders, high caffeine, alcohol, smoking, illegal drug consumption, pregnancy, breastfeeding, history of seizures, tinnitus, age under 18 or over 50 years, metal or magnetic pieces in the head, history of major head trauma or of migraine, hearing loss and a history of heart or brain diseases. 200 theta wave pulses 5 Hz for 15 min, with 80% motor threshold (600 pulses in total).
Right dorsolateral prefrontal cortex.
MagVenture MagPro x 100, with option (MagVenture, Farum, Denmark.
Electromyograph.
No reliable effect of stimulating theta bursts on the modulation of emotional response was found.
Deppermann et al., 201533
Emotional regulation in specific phobia
PEDro Score: 3
40 patients with spider phobia and 40 healthy control subjects.
No age references.
Sham-controlled, design.
Specific phobia (arachnophobia) Left prefrontal cortex. Galvanic response
Heart rate
No conclusive results.
Notzon et al., 201534
Specific phobia (arachnophobia)
PEDro Score: 10
41 patients with spider phobia and 42 healthy subjects.
Age range 18-65.
Single-blind, randomized, sham-controlled parallel-group trial design.
Specific phobia (arachnophobia).
Between 18 and 65 years.
Pregnancy.
Severe somatic disorders.
Other psychiatric disorders
Use of psychotropic or psychotropic drugs.
Contraindications to the use of TMS.
80% motor threshold.
15 pulses/s; 2 s of trains every 10 s total 3 min.
Right dorsolateral prefrontal cortex.
Galvanic response
Heart rate
No effect on the subjective and psychological reaction against virtual reality.
Low frequency rTMS usually offers patients anxiolytic effects.
Downar et al., 201635
Depression
PEDro Score: 0
Review article. Magstim 200 stimulator Very effective for major or refractory depressive disorders and for other psychiatric disorders, the results are still conservative.
Pallanti et al., 201036
Social anxiety
PEDro Score: 4
15 right-handed patients with social anxiety disorder and 15 healthy controls subjects.
Age range 21-73.
2 groups trials design.
Disorder of anxiety social.
Right-handed.
Other psychiatric disorders
Head injury.
Neurological diseases.
Endocrinological disorders
10 pulses varying between 100, 110, 120, 130, 140 and 150% of motor threshold.
Stimulation of the primary motor cortex.
The Liebowitz Social Phobia Scale.
The Tridimensional Patiently Questionnaire.
The Temperament and Character Inventory.
Electromyographic activity.
Induced the release of endogenous dopamine in the ipsilateral caudate nucleus.
Baeken et al., 201037
Emotional processing
PEDro Score: 10
20 patients righthanded healthy females.
Mean age 23.3
2 randomized groups trials design.
Right-handed
Medication free.
10 Hz at 110% motor threshold.
40 trains with a duration of 3.9 s, separated by intervals of 26.1 s.
Each session lasted 20 min with 1,560 pulses.
Right dorsolateral prefrontal cortex.
Magstim high-speed stimulator.
Magnetic resonance.
De Raedt et al., 201038
Emotional processing of emotional information
PEDro Score: 9
37 females.
Age range 19-30.
Single-blind randomized crossover within-subjects design.
Right-handed
Medication free
Between 19 and 30 years.
History of other psychiatric or ongoing conditions. 10 Hz
40 trains of 3.9 s with 26.1 s intervals.
1560 pulses per session.
Left dorsolateral prefrontal cortex.
Magstim high-speed magnetic stimulator.
MINI-international Neuropsychiatric Interview.
Beck depression inventory.
Emotional processing is affected.
Montovani et al., 200739
Panic with comorbidity with major depressive
PEDro Score: 6
6 patients, 3 females and 3 males.
Mean age 50.
Open label trial design.
Diagnosis for panic disorder according to the diagnostic criteria of DSM-IV-TR and major depression.
Drug intolerance.
4 daily trains at 100% of the engine threshold.
1 Hz for 5 min and with 2 min interval between trains.
1,200 stimuli per day for 10 days.
Stimulation of the right dorsolateral prefrontal cortex.
Magstim Super Rapid Stimulator. Without side effects, however, it was found that anticonvulsants can alter the response to rTMS. A clinically significant improvement of 5 out of 6 patients (50% in symptom measurement scales).
No differences between patients with medication and without medication
Mantovani et al., 201240
Panic with comorbidity with major depressive
PEDro Score: 10
25 patients, 13 females and 12 males.
Age range 18-65.
4-week double-blind, and 4-week open-label design.
Patients between 18 and 65 years.
Diagnosis of panic disorder and major depressive.
Stable psychotherapeutic or psychopharmacological treatment of at least 3 months and 4 weeks, respectively.
significant risk of suicide.
History of bipolar disorder, psychotic or substance use or abuse. With neurological diseases, with risk of seizures.
Unstable medical conditions.
Metal prostheses or implants.
Pregnancy or breastfeeding
1 Hz
30 min train
1 800 pulses per day.
At 110% of the engine idle threshold, for 5 days a week, for 4 weeks.
Stimulation of the right dorsolateral prefrontal cortex.
Magstim Super Rapid Stimulator. 40% reduction in panic symptoms.
50% reduction in depression symptoms.
Zwanzger et al., 200641
Panic attack
PEDro Score: 6
11 patients, six females, and five males.
Age range 25-27.
1 Hz real or sham rTMS in two separate sessions with a 7-d interval design.
Medication free. Diagnosis of other psychiatric diseases. 1 Hz in 2 separate sessions with an interval of 7 days.
120% related to the idle engine threshold.
1 800 stimuli.
1 train of 30 min.
Right dorsolateral prefrontal cortex.
Magstim Super Rapid Stimulator. Induction of the panic attack with 50 mg of CCK-4.
Panic symptoms evaluated with the Acute Panic Inventory (API).
First study of the effects of rTMS with experimental panic attack induction is investigated.
rTMS did not affect the panic induced by the CCK-4.
Effects of rTMS on induced panic do not achieve the efficacy of a standard pharmacological intervention.
Only one session was applied.
Machado et al., 201442
Panic with comorbidity of depression
PEDro Score: 0
1 female.
Age 34.
3 times/week during 4 weeks.
Disorder refractory to pharmacological treatment and cognitive behavioral psychotherapy.
Parkinson's disease
3 times a week, 4 weeks for a month.
Right DLPFC
1 Hz (inhibitory).
120% related to the idle engine threshold.
15 min.
Left DLPFC
10 Hz (excitatory).
120% related to the idle engine threshold.
15 min.
Right and left dorsolateral prefrontal cortex.
Level of depression and anxiety improved after 3 weeks.
After 4 weeks, the patient improved slightly.
High frequency antidepressant effect.
Deppermann et al., 201443
Panic with agoraphobia
PEDro Score: 11
23 patients control group and 44 patients with panic disorder.
Mean age 35.7
Randomized to sham or verum group design
Diagnosis of panic disorder. Under 18 years and over 65 years.
Pregnancy and severe somatic disorders.
Cardiovascular and neurological diseases; epilepsy.
Unstable psychopharmacological treatment or with benzodiazepines, tricyclic antidepressants and antipsychotics.
15 daily applications for 3 weeks.
Stimulation of theta burst.
600 pulses applied in bursts of 15 pulses per s, 2-s trains, every 10 s.
80% motor threshold.
Left dorsolateral prefrontal cortex.
Magstim 9925-00
Magstim Rapid2 Stimulator T/N 3567-23-02
No strong results were found.
Li H et al., 201444
Panic
PEDro Score: 0
40 patients
Age range 18-65
Randomized controlled trials
Diagnosis of panic disorder. 1 Hz for 2 or 4 weeks.
Right dorsolateral prefrontal cortex.
Reduction of symptoms of panic compared to simulated stimulation.
Balderston et al., 202045
Fear and anxiety
PEDro Score: 7
25 patients.
Mean age 29.11.
Double-blinded sham design.
Age 8-50, English speakers. 25 patients.
Mean age 29.11.
Double-blinded sham design.
1 Hz for 870 seconds.
100% of motor threshold.
MagVenture MagPro X100. (MagVenture Inc., Alpharetta GA stimulator. rTMS reduced both fear- and anxiety- potentiated startle, but did not affect the online anxiety ratings.

FundingThis paper was supported by the Instituto Politécnico Nacional (SIP 20200614) and the Consejo Nacional de Ciencia y Tecnología (CONACyT).

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were

performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Received: December 12, 2020; Accepted: May 19, 2021

* Correspondence:Claudia L. Martínez-González E-mail: clmartinezg@ipn.mx

Conflicts of interest

We declare no conflicts of interest.

Creative Commons License Instituto Nacional de Cardiología Ignacio Chávez. Published by Permanyer. This is an open access article under the CC BY-NC-ND license